# First in Human of Single and Multiple Doses of MOR106

> **NCT02739009** · PHASE1 · COMPLETED · sponsor: **Lakefront Biotherapeutics NV** · enrollment: 81 (actual)

## Conditions studied

- Healthy
- Dermatitis, Atopic

## Interventions

- **DRUG:** MOR106 single ascending doses, intravenous
- **DRUG:** Placebo single ascending doses, intravenous
- **DRUG:** MOR106 multiple ascending doses, intravenous
- **DRUG:** Placebo multiple intravenous administrations

## Key facts

- **NCT ID:** NCT02739009
- **Lead sponsor:** Lakefront Biotherapeutics NV
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-04
- **Primary completion:** 2017-08-01
- **Final completion:** 2017-08-01
- **Target enrollment:** 81 (ACTUAL)
- **Last updated:** 2017-10-05

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02739009

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02739009, "First in Human of Single and Multiple Doses of MOR106". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT02739009. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*